I thought we would be getting a lot more PR's and company calls. I only saw Pharmasset with a call today. Perhaps with most of the posters presented on the 4th they'll come later.
The lead-in phase can also assist in patient selection: patients with low baseline viral load and RVR, who do not require the addition of a protease inhibitor (these pts will most likely achieve SVR anyway), and non responders to PEG-IFN/RBV who might receive functional monotherapy by addition of a protease inhibitor.
Market Data 
Markets 
AI
